Efficacy of JAK inhibitors in Ulcerative Colitis

J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S737-S745. doi: 10.1093/ecco-jcc/jjz202.


Janus kinase [JAK] inhibitors are a completely novel therapy for the treatment of patients with immune-mediated inflammatory disorders. The oral formulation of tofacitinib has recently been approved for the treatment of moderate-to-severe ulcerative colitis. In the placebo-controlled OCTAVE programme, tofacitinib proved to be efficacious for both inducing and maintaining clinical remission, and this both in anti-tumour necrosis factor-naïve and exposed patients. Several other anti-JAK inhibitors are currently explored. This review summarises the available efficacy data from all anti-JAK inhibitors in ulcerative colitis.

Keywords: JAK inhibition; efficacy; tofacitinib; ulcerative colitis; upadacitinib.

Publication types

  • Review

MeSH terms

  • Adamantane / analogs & derivatives
  • Adamantane / therapeutic use
  • Colitis, Ulcerative / drug therapy*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Janus Kinase Inhibitors / therapeutic use*
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Piperidines / therapeutic use
  • Pyrimidines / therapeutic use
  • Treatment Outcome


  • Heterocyclic Compounds, 3-Ring
  • Janus Kinase Inhibitors
  • Piperidines
  • Pyrimidines
  • Niacinamide
  • upadacitinib
  • tofacitinib
  • peficitinib
  • Adamantane